Multiple endocrine neoplasia - Revision history

Rossdonaldson1: /* References */

2023-03-01T17:12:46Z

References

← Older revision		Revision as of 17:12, 1 March 2023
Line 47:		Line 47:
	==References==		==References==
	<references/>		<references/>

			[[Category:Heme/Onc]]

Rossdonaldson1: /* Background */

2023-01-04T18:20:37Z

Background

← Older revision		Revision as of 18:20, 4 January 2023
Line 1:		Line 1:
	==Background==		==Background==
			[[File:Multiple endocrine neoplasia.png\|thumb\|MEN findings by type.]]
	*Autosomal dominant predisposition to tumors within endocrine organs/glands		*Autosomal dominant predisposition to tumors within endocrine organs/glands
	*Classified into two distinct syndromes, multiple endocrine neoplasia type 1 (MEN1), and multiple endocrine neoplasia type 2 (MEN2)		*Classified into two distinct syndromes, multiple endocrine neoplasia type 1 (MEN1), and multiple endocrine neoplasia type 2 (MEN2)

Rossdonaldson1 at 18:18, 4 January 2023

2023-01-04T18:18:41Z

← Older revision		Revision as of 18:18, 4 January 2023
Line 9:		Line 9:
	***Most common manifestation of MEN1<ref>Al-Salameh A, Cadiot G, Calender A, Goudet P, Chanson P. Clinical aspects of multiple endocrine neoplasia type 1. Nat Rev Endocrinol. 2021 Apr;17(4):207-224. doi: 10.1038/s41574-021-00468-3. Epub 2021 Feb 9. PMID: 33564173.</ref>		***Most common manifestation of MEN1<ref>Al-Salameh A, Cadiot G, Calender A, Goudet P, Chanson P. Clinical aspects of multiple endocrine neoplasia type 1. Nat Rev Endocrinol. 2021 Apr;17(4):207-224. doi: 10.1038/s41574-021-00468-3. Epub 2021 Feb 9. PMID: 33564173.</ref>
	**Pituitary adenomas		**Pituitary adenomas
	**Pancreatic islet cell/GI endocrine tumors (e.g., [[Zollinger-Ellison ~~Syndrome~~]], [[Insulinoma]])		**Pancreatic islet cell/GI endocrine tumors (e.g., [[Zollinger-Ellison syndrome]], [[Insulinoma]])
	*MEN2A:		*MEN2A:
	**Primary [[hyperparathyroidism]]		**Primary [[hyperparathyroidism]]

Kennybroccoli: /* Evaluation */

2022-12-13T22:51:01Z

Evaluation

← Older revision		Revision as of 22:51, 13 December 2022
Line 23:		Line 23:

	==Evaluation==		==Evaluation==
			*MEN1: Should be suspected in any patient with two or more primary MEN1 tumor types
			*MEN2: Should be suspected in any patient with medullary thyroid cancer or [[pheochromocytoma]]
	===Workup===		===Workup===

	===Diagnosis===		===Diagnosis===
			*Clinical diagnosis with confirmatory genetic testing
			**MEN1: Germline MEN1 mutation
			**MEN2: Germline RET mutation

	==Management==		==Management==

Kennybroccoli: /* Clinical Features */

2022-12-13T22:45:54Z

Clinical Features

@@ Line 5: / Line 5: @@
 ==Clinical Features==
+*MEN1:
 ==Differential Diagnosis==

Kennybroccoli: /* Background */

2022-12-13T22:39:15Z

Background

← Older revision		Revision as of 22:39, 13 December 2022
Line 1:		Line 1:
	==Background==		==Background==
			*Autosomal dominant predisposition to tumors within endocrine organs/glands
			*Classified into two distinct syndromes, multiple endocrine neoplasia type 1 (MEN1), and multiple endocrine neoplasia type 2 (MEN2)
			**Type 2 further subclassified into MEN2A and MEN2B

	==Clinical Features==		==Clinical Features==

Kennybroccoli: Created page with "==Background== ==Clinical Features== ==Differential Diagnosis== ==Evaluation== ===Workup=== ===Diagnosis=== ==Management== ==Disposition== ==See Also== ==External Links== ==References== "

2022-12-13T22:30:51Z

Created page with "==Background== ==Clinical Features== ==Differential Diagnosis== ==Evaluation== ===Workup=== ===Diagnosis=== ==Management== ==Disposition== ==See Also== ==External Links== ==References== <references/>"

New page

==Background==

==Clinical Features==

==Differential Diagnosis==

==Evaluation==
===Workup===

===Diagnosis===

==Management==

==Disposition==

==See Also==

==External Links==

==References==
<references/>